The biggest names in diabetes tech gathered in New Orleans last weekend for the American Diabetes Association’s 86th Scientific Sessions (ADA 2026). Clinical findings supporting next-generation automated insulin delivery platforms, continuous glucose monitors (CGMs) and all kinds of other technologies were on display in New Orleans. BTIG analysts Marie Thibault, Alexandra Pang and Sam Eiber […]
biolinq
Biolinq data backs autonomous, needle-free CGM
Biolinq today shared new clinical findings supporting the use of its autonomous, needle-free continuous glucose monitor (CGM). San Diego-based Biolinq develops the Shine sensor, which integrates glucose, activity and sleep information into a single device with autonomous operation. The first-of-its-kind system utilizes a patch on the forearm to provide real-time glucose feedback through a primary […]
The top CGM stories of 2025
Millions of people worldwide are looking for ways to manage their diabetes. That’s where the continuous glucose monitor (CGM) comes in. The CGM market is expected to experience substantial, double-digit percentage growth over the next five years, reaching nearly $29 billion by 2030. Market leaders Abbott and Dexcom continue to establish their hold on the […]
Biolinq wins FDA de novo nod for autonomous, needle-free CGM
Biolinq announced today that it received FDA de novo clearance for its lead product, the Biolinq Shine wearable biosensor. San Diego-based Biolinq can now scale its new generation of wearable sensors designed for comfort, simplicity and global reach. Its Shine sensor integrates glucose, activity and sleep information into a single device with autonomous operation. The […]
The biggest diabetes tech stories out of ADA 2025
The biggest names in diabetes tech gathered in Chicago this past weekend for the American Diabetes Association’s 85th Scientific Sessions. At last year’s edition in Orlando, type 2 diabetes dominated the conversation. This time around, type 2 remained a hot topic, alongside new players in the continuous glucose monitor (CGM) and automated insulin delivery market, […]
Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy
A new study has demonstrated proof of concept for a Biolinq continuous sensor in preventing muscle loss during GLP-1 therapy. Investigators presented findings as a late-breaking poster at the American Diabetes Association’s 85th Scientific Sessions in Chicago. Using a DNA-based bioreceptor (aptamer), Biolinq designed its sensor to detect phenylalanine, an essential amino acid. Released from […]
Biolinq closes $100M Series C funding round for biosensor platform
Biolinq said today it has closed a $100 million Series C funding round to advance its biosensor platform. “This financing will bolster Biolinq’s commercial readiness efforts while we pursue regulatory approval for the first intradermal glucose sensor that incorporates activity and sleep information into a single wearable device,” Biolinq CEO Rich Yang said in a […]
Biolinq raises $58M to support intradermal glucose sensor
Biolinq announced today that it completed a $58 million financing to support the progression of its proprietary intradermal glucose sensor. Alpha Wave Ventures led the funding round. Niterra’s corporate venture capital fund jointly operated with Pegasus Tech Ventures also participated. Other contributors included existing investors RiverVest Venture Partners, AXA IM Alts, Global Health Investment Corporation, […]
Biolinq names new CEO
Wearable biosensor technology developer Biolinq announced today that it named Richard Yang as its new CEO. San Diego-based Biolinq, which develops biosensor platforms to measure continuous glucose for managing diabetes, among other clinical conditions, said in a news release that Yang is a veteran of more than 20 years with time spent at top-tier medical device companies. […]
Biolinq adds $5m to Series A
Biosensor developer Biolinq said today that it raised $4.8 million as an extension of its Series A financing round. The San Diego-based company said that the investment in its expanded, oversubscribed Series A round was led by the JDRF T1D Fund, Aphelion Capital and LifeSci Venture Partners. With the additional funding, Biolinq said it raised a […]
